You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Advancing clemizole for hepatitis C: towards a pre-IND package
SBC: EIGER GROUP INTERNATIONAL, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new target within the HCV non-structural protein NS4B, consist ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Advance Early Detection of Lupus Nephritis with ClearGold
SBC: CLEARNANO INC Topic: 400SummarySystemic lupus erythematosusSLEor lupus is an autoimmune disease that impacts more thanmillion people worldwideincludingmillion AmericansNearlyof these patients will develop lupus nephritiswhich can cause kidney failureAs a resultits financial burden to individual patient can reach $yearmuch higher than many other diseases because of kidney transplantationAlthough early treatment of lupus n ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma
SBC: Avenzoar Pharmaceuticals, Inc. Topic: 102ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A cost-effective bioreactor to advance functional tissue engineering of cartilage
SBC: Apex Biomedical Company, LLC Topic: NIAMSDESCRIPTION (provided by applicant): Osteoarthritis (OA) is the leading cause of chronic disability in the United States. A clinical goal in the treatment and prevention of OA is to develop replacement cartilage using tissue engineering (TE) technologies. Although TE cartilage presently lacks the mechanical stability of native cartilage, studies have demonstrated that mechanical stability can be e ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Accelerate Adoption of Galaxy Pro in the Biomedical Research Marketplace
SBC: GalaxyWorks LLC Topic: NHGRIProject Summary Galactic Core LLC aims to develop a robust, scalable, and managed service for performing enterprise-grade biomedical data analysis. The service will be based on the popular open-source Galaxy application (https://galaxyproject.org/), offering unlimited data storage and compute capabilities with an extremely powerful, flexible, and collaborative environment for analyzing data. ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health